A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults with Chronic Inducible Urticaria

Evommune

Status and phase: Enrolling; Phase 2

Conditions: Chronic Inducible Urticaria

Treatments: Drug: Oral EVO756

Study type: Interventional

Funder types: Industry

Identifiers

NCT06603220

EVO756-CIU001

Details and patient eligibility

About

This phase 2a trial will evaluate the safety and efficacy of EVO756 in subjects with chronic inducible urticaria, including symptomatic dermographism and cold urticaria.

Enrollment: 30 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Confirmed diagnosis of chronic inducible urticaria for at least 3 months.
• Positive response following provocation using the TempTest or FricTest at Screening and Day 1.

Exclusion criteria

• History of diseases other than chronic inducible urticaria or chronic spontaneous urticaria with urticaria or angioedema symptoms, such as urticarial vasculitis, erythema multiforme, cutaneous mastocytosis (urticaria pigmentosa), and hereditary or acquired angioedema.
• Concurrent use of certain medications, including antihistamines.
• Any clinically significant disease, or other skin disease or skin markings (e.g., extensive scarring, tattoos), that might confound the evaluation of safety or efficacy.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

EVO756

Experimental group

Treatment:

Drug: Oral EVO756